First Affiliated Hospital of Wannan Medical College
皖南医科大学第一附属医院
Listed for 10 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.
Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.
No official website checked for this hospital yet.
Research at First Affiliated Hospital of Wannan Medical College
Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.
Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed
- Oesophageal squamous cell carcinoma食管鳞状细胞癌3 papers led
- Hepatocellular carcinoma肝细胞癌15 papers led
- Stomach cancer胃癌22 papers led
- Osteosarcoma骨肉瘤3 papers led
- Ewing sarcoma尤文肉瘤0 papers led
- Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
- Haemophilia A血友病 A1 paper led
- Amyotrophic lateral sclerosis肌萎缩侧索硬化症0 papers led
- Behçet disease白塞病1 paper led
- IgA nephropathyIgA 肾病0 papers led
Not listed for: Nasopharyngeal carcinoma, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.
Cancer
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 3 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wuhu for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma
No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led3
- WTAP Mediated m6A Modification Stabilizes PDIA3P1 and Promotes Tumor Progression Driven by Histone Lactylation in Esophageal Squamous Cell Carcinoma.
- A positive feedback between PDIA3P1 and OCT4 promotes the cancer stem cell properties of esophageal squamous cell carcinoma.
- Lipid Identification of Biomarkers in Esophageal Squamous Cell Carcinoma by Lipidomic Analysis.
All its trials on ClinicalTrials.gov, any status1
More papers found outside PubMed (not counted)3
- Minimally Invasive Inflatable Mediastinoscope-Assisted Laparoscopic Esophagectomy for Esophageal Cancer: Case Series and Review
- 187P Effectiveness, safety, and patterns of use of camrelizumab in advanced esophageal cancer: An individual patient data (IPD) pooled analysis of 987 patients from three prospective observational cohort studies
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
Cancer
Hepatocellular carcinoma
肝细胞癌Led 15 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wuhu for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma
No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led15
- Potential Roles of Serum Exosomal CD155 and its Impact on NK Cell Immunosuppression in Hepatocellular Carcinoma.
- GCNT3 Promotes Hepatocellular Carcinoma Progression and EMT by Activating the PI3K/AKT Pathway.
- Emerging importance of m6A modification in liver cancer and its potential therapeutic role.
- Viral-Track integrated single-cell RNA-sequencing reveals HBV lymphotropism and immunosuppressive microenvironment in HBV-associated hepatocellular carcinoma.
- Ciclopirox, a broad-spectrum antifungal drug, moonlights as a pyroptosis agonist to drive hepatocellular carcinoma cell death.
- Integrating machine learning and molecular docking to decipher the molecular network of aflatoxin B1-induced hepatocellular carcinoma.
- Heparanase and MMP-9 synergistically induce endothelial-mesenchymal transition in portal vein microvessels to promote hepatocellular carcinoma metastasis.
- Glycosyltransferase B4GALNT1 promotes immunosuppression in hepatocellular carcinoma via the HES4-SPP1-TAM/Th2 axis.
- Association of APC Expression with Its Promoter Methylation Status and the Prognosis of Hepatocellular Carcinoma.
- Comprehensive genomic signature of pyroptosis-related genes and relevant characterization in hepatocellular carcinoma.
- Different Approaches of Laparoscopic Mesohepatectomy for Centrally Located Hepatocellular Carcinomas.
- ncRNA-Regulated LAYN Serves as a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Hepatocellular Carcinoma: A Bioinformatics Analysis.
- Adiponectin and the risk of gastrointestinal cancers in East Asians: Mendelian randomization analysis.
- Hepatitis B virus PreS2 mutants in liver cancer patients.
- Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?
Chinese-language papers (not in the count)1
Cancer
Stomach cancer
胃癌Led 22 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.2%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
1 hospital in Wuhu for stomach cancer218 hospitals in China for stomach cancer
Open trials with this hospital 2
Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.
- RecruitingClinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- Phase
- Phase 1
- Started
- 2023-11
- Registry
- NCT06126406
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteWuhu
- RecruitingS-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
- Phase
- Phase 3
- Started
- 2019-01
- Registry
- NCT03941561
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesHefei, Nanchang, Wuhu
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led22
- NAT10-Mediated N4-Acetylcytidine Modification of GRB7 Promotes the Progression of Gastric Cancer.
- A rare early gastric mixed neuroendocrine-non-neuroendocrine neoplasm misdiagnosed as early gastric cancer.
- Nomogram Based on Body Composition and Prognostic Nutritional Index Predicts Survival After Curative Resection of Gastric Cancer.
- Targeting SOX13 inhibits assembly of respiratory chain supercomplexes to overcome ferroptosis resistance in gastric cancer.
- A novel, safe and feasible gastrojejunal anastomosis after laparoscopic-assisted distal gastrectomy for gastric cancer: Pants-shaped anastomosis (with video).
- A novel, safe and feasible esophagojejunal anastomosis for total gastrectomy: Pants-shaped anastomosis (with video).
- Overexpression of TYRO3 indicates poor prognosis and induces gastric cancer progression via AKT-mTOR pathway.
- Prognosis value and positive association of Rab1A/IL4Rα aberrant expression in gastric cancer.
- SOV sensitizes gastric cancer cells to radiation by suppressing radiation-induced autophagy in vitro and in vivo.
- The clinical effectiveness of establishing a proximal jejunum pouch after laparoscopic total gastrectomy: A propensity score-based analysis.
- Laparoscopic enucleation for gastric leiomyoma in the antrum (with video).
- GGT5 Is an Independent Prognostic Biomarker in Stomach Adenocarcinoma.
- Adiponectin and the risk of gastrointestinal cancers in East Asians: Mendelian randomization analysis.
- M6 A demethylase fat mass and obesity-associated protein regulates cisplatin resistance of gastric cancer by modulating autophagy activation through ULK1.
- TULP3 silencing suppresses cell proliferation, migration and invasion in gastric cancer via the PTEN/Akt/Snail pathway.
- Clinical Study on the Evaluation of the Condition of Patients with Gastric Tumors and the Choice of Surgical Treatment by Gastric Ultrasonic Filling Method.
- Activation of MAT2A-ACSL3 pathway protects cells from ferroptosis in gastric cancer.
- Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer.
- Clinical characteristics and risk factors for upgraded pathology in patients with gastric intraepithelial neoplasia after endoscopic submucosal dissection.
- Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer.
- Absent in melanoma 2 suppresses gastric cancer cell proliferation and migration via inactivation of AKT signaling pathway.
- Spontaneous acute epidural hematoma associated with chronic subdural hematoma due to dural metastasis of gastric carcinoma: a case report and literature review.
All its trials on ClinicalTrials.gov, any status7
- Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) for CEA Positive Advanced Malignant Solid Tumors
- S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC)
- To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
- XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
- Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor
- Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.
- Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (SEIPLUS)
Cancer
Osteosarcoma
骨肉瘤Led 3 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.1%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
2 hospitals in Wuhu for osteosarcoma742 hospitals in China for osteosarcoma
No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led3
Earlier papers (2016–2020)1
Cancer
Ewing sarcoma
尤文肉瘤Led no English-language PubMed papers on Ewing sarcoma in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wuhu for Ewing sarcoma139 hospitals in China for Ewing sarcoma
No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Earlier papers (2016–2020)1
Blood disorders
Haemophagocytic lymphohistiocytosis
噬血细胞性淋巴组织细胞增生症Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wuhu for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis
No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Papers it led2
Chinese-language papers (not in the count)1
More papers found outside PubMed (not counted)1
Blood disorders
Haemophilia A
血友病 ALed 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wuhu for haemophilia A160 hospitals in China for haemophilia A
No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Other diseases
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led no English-language PubMed papers on amyotrophic lateral sclerosis in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wuhu for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis
No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Earlier papers (2016–2020)1
Other diseases
Behçet disease
白塞病Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
1 hospital in Wuhu for Behçet disease149 hospitals in China for Behçet disease
No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
Other diseases
IgA nephropathy
IgA 肾病Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.
- Papers led
- 0
- 2021–2025
- Trials led
- 0
- any status, ClinicalTrials.gov
- Open trials led
- 0
- recruiting or about to
- Open trials as a site
- 0
- led by another institution
3 hospitals in Wuhu for IgA nephropathy346 hospitals in China for IgA nephropathy
No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.
The records behind these numbers
Hospital name read automatically from author addresses, not yet checked by hand.
All its trials on ClinicalTrials.gov, any status1
Getting in touch
Name card to show staff or a driver
皖南医科大学第一附属医院
First Affiliated Hospital of Wannan Medical College
芜湖
Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.
Inquiry letter in English and Chinese
Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.
Records hospitals usually ask for
- A recent summary or letter from the treating doctor
- Pathology report
- Scans (CT, MRI, PET) with their reports, and the images if possible
- Treatments so far, with dates
- Current medicines
What to do next
Where these numbers come from
Papers
English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions
Trials
ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.